abstract |
A method of predicting the sensitivity of a cancer patient to treatment with a human double minute inhibitor 2 (MDM2i), the method comprising: evaluating the gene expression of more than one biomarker selected from Table 2, ** Formula ** in a cancer sample obtained from the patient, where a biomarker selected from Table 2 is Mdm2; and gene expression of more than one biomarker indicates that the patient is sensitive to treatment with an MDM2i. |